Holger Lode

from Wikipedia, the free encyclopedia
Holger Lode

Holger Lode (born April 14, 1967 in Pfullendorf ) is a German specialist in pediatrics . He is a university professor, head of general paediatrics and pediatric hematology and oncology as well as managing director of the Center for Pediatric Medicine at the University Medical Center Greifswald . Lode is known for his work in the field of immunotherapy for neuroblastoma .

Life

Lode studied medicine from 1986 to 1993 at the University of Tübingen and at Brown University , USA. After receiving his doctorate (summa cum laude) in 1993, he was licensed by the Baden-Württemberg Medical Association in 1995. In 1994 he began training as a specialist in paediatrics at the University Children's Hospital in Tübingen. With a research grant from the German Research Foundation, he went to the Scripps Research Institute , USA (Department of Immunology, Laboratory for Tumor Immunology) as a postdoc in 1996 and accepted the position of Assistant Professor in 1999. In 2000 he continued his specialist training in pediatrics at the Clinic for General Pediatrics / Bone Marrow Transplantation at the Charité - Universitätsmedizin Berlin and graduated in 2003. He completed his habilitation in 2003 on strategies for immunotherapy in neuroblastoma and received the Venia Legendi in pediatrics at the Charité. Further emphases followed in the areas of pediatric intensive care medicine in the field of pediatric and adolescent medicine (2005) and pediatric hematology and oncology (2006). From 2005 to 2009 Lode was senior physician in charge of the Clinic for General Pediatrics and the Clinic for Pediatric Hematology and Oncology at the Charité, as well as Deputy Clinic Director of the Clinic for General Pediatrics / Bone Marrow Transplantation. Alongside his job, he completed a distance learning course in business administration in the hospital from 2006 to 2007 and, in 2009, accepted a professorship for paediatrics at the University Medical Center Greifswald, Medical Faculty of the Ernst-Moritz-Arndt University of Greifswald . This position is linked to the management of the General Pediatrics / Pediatric Hematology and Oncology departments as well as to the role of Managing Director of the Center for Pediatric and Adolescent Medicine. Since 2013 he has been chairman of the doctoral committee at the University Medical Center Greifswald.

Scientific contribution

During his time at the Scripps Institute, Lode developed a tumor model to investigate immunotherapeutic approaches to neuroblastoma , a malignant disease of the sympathetic nervous system that occurs primarily in early childhood. Lode showed that treatment with antibody-cytokine fusion proteins called immune cytokines is efficient in this model. He also demonstrated a synergetic effect with inhibitors of new blood vessel formation and with tumor vaccines. This fundamental scientific discovery has been put into clinical application and is currently the subject of numerous clinical studies. As the first Emmy Noether junior research group leader of the DFG at the Charité, Lode developed new approaches that enabled the treatment of malignant tumors through genetic vaccinations. In particular, the combination of DNA vaccinations with tumor-specific immunocytokines was an important step in the optimization of DNA vaccinations . Since joining the SIOPEN Group in 2002, Lode has been involved in the clinical development of a monoclonal antibody against ganglioside GD2 (ch14.18 / CHO). He was the first to succeed in establishing a new method of administration for this antibody. He is currently leading two international clinical studies in children with neuroblastoma with this antibody.

Memberships in scientific associations

Lode was and is a member of numerous German, European and American scientific associations. These include the German Society for Child and Adolescent Medicine , the American Association of Cancer Research , the American Society of Hematology , the American Association of Immunologists and the American Society of Clinical Oncology . Since 2013 he has been a member of the Advisory Scientific Committee of the International Society for Pediatric Oncology Europe Neuroblastoma (SIOPEN) , Chairman of the Immunotherapy Committee of SIOPEN and a member of the Scientific Committee of the International Society for Pediatric Oncology (SIOP SPAC Member).

honors and awards

  • 2007 Merit Award, American Society of Clinical Oncology
  • 2005 Science4life, Venture Cup
  • 2000 Heinrich Finkelstein Prize, North German Society for Pediatrics and Adolescent Medicine, Lübeck
  • 1998 Young Investigator Award, American Association of Cancer Research, New Orleans, USA
  • 1998 Young Investigator Award, Advances in Neuroblastoma Research, Bath, UK

Publications

Web links

Individual evidence

  1. ↑ a b Clinic and Polyclinic for Pediatric and Adolescent Medicine: Univ.-Prof. Dr. med. Holger Lode. Retrieved July 6, 2019 .
  2. ↑ Holger Lode's curriculum vitae, University Medicine Greifswald
  3. ^ Habilitation thesis Holger Lode
  4. ↑ Home: University Medicine Greifswald. Retrieved July 6, 2019 .
  5. ↑ HN Lode, R. Xiang, NM Varki, CS Dolman, SD Gillies, RA Reisfeld: Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. In: Journal of the National Cancer Institute. 89, 1997, pp. 1586-1594.
  6. ↑ HN Lode, R. Xiang, T. Dreier, NM Varki, SD Gillies, RA Reisfeld: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. In: Blood. 91, 1998, pp. 1706-1715.
  7. ↑ HN Lode, T. Moehler, R. Xiang et al .: Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. In: Proc Natl Acad Sci US A. 96, 1999, pp. 1591-1596.
  8. ↑ HN Lode, R. Xiang, SR Duncan et al .: Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. In: Proc Natl Acad Sci US A. 96, 1999, pp. 8591-8596.
  9. ↑ HN Lode, R. Xiang, U. Pertl et al: Melanoma immunotherapy by targeted IL-2 depends on CD4 (+) T-cell help mediated by CD40 / CD40L interaction [In Process Citation]. In: J Clin Invest. 105, 2000, pp. 1623-1630.
  10. ↑ S. Fest, N. Huebener, M. Bleeke et al: Survivin minigene DNA vaccination is effective against neuroblastoma. In: Int J Cancer. 125, 2009, pp. 104-114.
  11. ↑ U. Pertl, H. Wodrich, JM Rühlmann, SD Gillies, HN Lode, RA Reisfeld: Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. In: Blood. 101, 2003, pp. 649-654.
  12. ↑ SIOPEN homepage
  13. ↑ Solving Kids' Cancer: Prof. Holger Lode at the NCCA UK Parent Conference 2014. January 29, 2015, accessed on July 6, 2019 .
  14. ↑ Y. Zeng, S. Fest, R. Kunert et al: Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK cells in mice. In: Mol Immunol. 42, 2005, pp. 1311-1319.
  15. ↑ Holger Lode Inventions, Patents and Patent Applications - Justia Patents Search. Retrieved July 6, 2019 .
  16. ↑ Long-Term Fusion Study (LTI). Retrieved July 6, 2019 .
  17. ↑ Phase II Study of Monoclonal Antibody ch14.18 / CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma - Full Text View - ClinicalTrials.gov. Accessed July 6, 2019 .
  18. ↑ SIOPEN, Immunotherapy Committee ( Memento from April 26, 2016 in the Internet Archive )
  19. ↑ SPAC Members | SIOP. Retrieved July 6, 2019 (American English).
  20. ↑ Science4Life ( Memento from April 14, 2016 in the Internet Archive )
personal data
SURNAME Lode, Holger
BRIEF DESCRIPTION German child and youth psychiatrist
DATE OF BIRTH April 14, 1967
PLACE OF BIRTH Pfullendorf